![]() In September, Decibel Therapeutics announced the publication of a study in Cell on noise-related inner ear damage that involved its data. Prior preclinical research found that DB-OTO restored functional otoferlin protein in mice and dose scaling and distribution in non-human primates.Ī Phase 1/2 trial is planned for DB-OTO in sensorineural hearing loss.Īlso at ARO, the company presented data on proprietary, cell-selective promoters for three of its gene therapy pipeline candidates. Before Decibel, Michael served as co-founder and senior vice president of research and development at Agios Pharmaceuticals. The most recent data showed that otoferlin expression increased for several weeks before plateauing, which was in line with prior research involving mice that achieved stable, functional recovery. Prior to joining Volastra, Michael was chief scientific officer of Decibel Therapeutics where he led the development of a gene therapy candidate for hearing loss. The firm's pipeline products comprise DB-ATO, AAV.103, AAV.104, AAV.201, DB-020, and Cochlear Hair Cell Regeneration.Ĭlick Here to get the full Stock Report for Decibel Therapeutics Inc stock.Decibel Therapeutics (NSDQ:DBTX) recently presented preclinical data for DB-OTO at the Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO).ĭB-OTO is a dual-vector adeno-associated virus (AAV) investigational gene therapy product candidate for individuals with hearing loss from mutations of the otoferlin gene. Its lead gene therapy product candidate is DB-OTO which provides hearing to individuals born with profound hearing loss due to an OTOF deficiency. Learn more about Decibel Therapeutics Incs (DBTX) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Biotechnology. Cambridge, Massachusetts, United States 51-100 Series D Public 15,167 Highlights Stock Symbol NASDAQ:DBTX Total Funding Amount 189. It aims to restore and improve hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair, and restore hearing. More About Decibel Therapeutics Incĭecibel Therapeutics Inc is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders. To screen for more stocks like Decibel Therapeutics Inc click here. So far 408,849 shares have traded compared to average volume of 136,346 shares. Decibel Therapeutics - Translating scientific advances in inner ear biology into novel therapies for people with hearing loss and tinnitus. The stock has traded between $4.63 and $5.30 so far today. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.ĭecibel Therapeutics Inc (DBTX) stock is trading at $5.18 as of 11:53 AM on Thursday, Feb 9, a gain of $0.87, or 20.19% from the previous closing price of $4.31. The options market is another place to get signals about sentiment. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Similarly, a stock that is in a downtrend must be out of favor. For a stock to go up, investors must feel good about it. Decibel Therapeutics Insider Transactions Over The Last Year. Price action is generally the best indicator of sentiment. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. ![]() When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. See Full DBTX Report What is Stock Sentiment?
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |